Prestige Consumer Healthcare (PBH) Operating Income (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Operating Income came in at $82.5 million in Q4 2025, down 10.3% year-on-year from $92.0 million in Q4 2024, and up 3.54% quarter-over-quarter from $79.7 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Operating Income (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Operating Income history runs 16 years deep, the most recent figure standing at $82.5 million for Q4 2025.
- On a quarterly basis, Operating Income fell 10.3% year-over-year to $82.5 million in Q4 2025; TTM through Dec 2025 was $322.3 million, a 2.47% decrease from a year earlier, with the FY2025 full-year figure at $336.8 million, down 1.65% from the prior year.
- Operating Income improved to $82.5 million in Q4 2025 per PBH's latest filing, from $79.7 million in the prior quarter.
- Across five years, Operating Income topped out at $92.0 million in Q4 2024 and bottomed at -$281.0 million in Q1 2023.
- The 5-year median for Operating Income is $83.5 million (2021), against an average of $64.6 million.
- Across the five-year window, Operating Income sank 462.93% in 2023 and surged 129.24% in 2024, its largest moves.
- Year by year, Operating Income stood at $82.6 million in 2021, then increased by 5.56% to $87.2 million in 2022, then declined by 0.4% to $86.8 million in 2023, then increased by 5.91% to $92.0 million in 2024, then declined by 10.3% to $82.5 million in 2025.
- Per Business Quant, the three latest PBH Operating Income figures stand at $82.5 million (Q4 2025), $79.7 million (Q3 2025), and $71.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 82.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 82.49 Mn |
| Sep 30, 2025 | 79.67 Mn |
| Jun 30, 2025 | 71.76 Mn |
| Mar 31, 2025 | 88.43 Mn |
| Dec 31, 2024 | 91.96 Mn |
| Sep 30, 2024 | 84.34 Mn |
| Jun 30, 2024 | 72.05 Mn |
| Mar 31, 2024 | 82.15 Mn |
| Dec 31, 2023 | 86.83 Mn |
| Sep 30, 2023 | 88.25 Mn |
| Jun 30, 2023 | 85.19 Mn |
| Mar 31, 2023 | -281.00 Mn |
| Dec 31, 2022 | 87.18 Mn |
| Sep 30, 2022 | 84.38 Mn |
| Jun 30, 2022 | 87.01 Mn |
| Mar 31, 2022 | 77.43 Mn |
| Dec 31, 2021 | 82.59 Mn |
| Sep 30, 2021 | 78.56 Mn |
| Jun 30, 2021 | 91.34 Mn |
| Mar 31, 2021 | 70.94 Mn |